摘要
目的 探讨降纤酶治疗急性脑梗死的疗效和安全性。 方法 1 0 6例发病在 72 h内的急性脑梗死患者随机分成治疗组和对照组 ,两组患者年龄、性别、伴发疾病和既往史积分、治疗前神经功能缺损程度评分相似 ,具有可比性。治疗组给降纤酶 1 0 u静脉滴注 ,每天 1次 ;对照组给东菱精纯克栓酶 (DF-52 1 ) 1 0 IU静脉滴注 ,隔天 1次 ,7天为 1个疗程。动态监测血浆纤维蛋白原浓度 ,并进行疗效和安全性评价。 结果 降纤酶具有降低纤维蛋白原浓度 ,治疗急性脑梗死的总有效率为 92 .4 5% ,与 DF-52 1比较无显著性差异 (P >0 .0 5) ,无不良反应。
Objective To investigate the efficacy and safety of defibrase in the treatment of acute ischemic cerebral infarction Methods 106 patients with acute ischemic cerebral infarction,which within the first 72 hours after the onset of the disease were randomly divided into study group and control groupBoth groups were similarity in age,sex,concomitant disease and anamnesis scores and neurologic deficit scores before medication,and had comparabilityThe study group were given defibrase 10u in 09% natrii chloridi 200ml,intravenous drip,qod for 7 daysThe control group received batroxobin 10u in 09% natrii chloridi 200ml,intravenous drip,qod for 7 days Plasma fibrinogen levels were monidored and the efficacy and safety were evaluated Results Defibrase can reduce plasma fibrinogen levels and total effective rate is 9245% for treating acute ischemic cerebral infarction,and there was no significant difference than batroxobin(P>005)Conclusion Defibrase is effective and safe drug for treating acute ischemic cerebral infarction
出处
《蛇志》
2000年第2期36-37,共2页
Journal of Snake
